Skip to main content
SpringerLink
Log in

Exenatide

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

In April 2005, exenatide (Byetta; Amylin/Eli Lilly) was approved by the US FDA as an adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes. It is the first in a new class of drugs that mimic the activity of natural glucoregulatory peptides known as incretins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Pathways of diabetic complications.

References

  1. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827 (2001).

    Article  CAS  Google Scholar 

  2. Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655 (1993).

    CAS  PubMed  Google Scholar 

  3. Joy, S. V. et al. Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. 39, 110–118 (2005).

    Article  CAS  Google Scholar 

  4. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021773lbl.pdf> (2005).

  5. Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635 (2004).

    Article  CAS  Google Scholar 

  6. Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091 (2005).

    Article  CAS  Google Scholar 

  7. DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100 (2005).

    Article  CAS  Google Scholar 

  8. U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995).

  9. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).

    Article  CAS  Google Scholar 

  10. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).

    Article  CAS  Google Scholar 

  11. International Diabetes Federation <http://www.idf.org/>.

  12. American Diabetes Association <http://www.diabetes.org/>.

  13. IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).

Download references

Author information

Authors and Affiliations

  1. Charles R. Drew University, Los Angeles, 90059, California, USA

    Mayer B. Davidson

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Guy Bate

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Mayer B. Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davidson, M., Bate, G. & Kirkpatrick, P. Exenatide. Nat Rev Drug Discov 4, 713–714 (2005). https://doi.org/10.1038/nrd1828

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1828

  • Springer Nature Limited

This article is cited by

Search

Navigation